A phase I study of a pooled synthetic long peptide mutant KRAS vaccine in patients with pancreatic cystic neoplasms at risk for developing pancreatic cancer.

作者
Kai-li Liang,Amanda L. Huff,Saurav Daniel Haldar,Anna K. Ferguson,Maureen Berg,Hao Wang,Julie M. Nauroth,Amy Morck Thomas,Nancy Sun,Dan A. Laheru,William Reece Burns,Richard Andrew Burkhart,Jin Peng He,Kelly J. Lafaro,Laura DeLong Wood,Michael Goggins,Elizabeth M. Jaffee,Nilofer Saba Azad,Neeha Zaidi
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (16_suppl)
标识
DOI:10.1200/jco.2025.43.16_suppl.tps2699
摘要

TPS2699 Background: Mutant KRAS (mKRAS) is an oncogenic driver expressed in > 90% of patients with pancreatic ductal adenocarcinoma (PDAC) and the majority of pancreatic precursors, including > 90% of intraductal papillary mucinous neoplasms (IPMNs) and pancreatic intraepithelial neoplasia (PanIN) (Kanda et al., 2012). If left untreated, approximately 40-60% of high-risk IPMNs will have malignant transformation (Fonseca et al., 2018). mKRAS vaccines have recently demonstrated encouraging results in generating mKRAS-specific T cell responses that correlate with clinical benefit in patients with resected PDAC. We previously reported that a mKRAS-targeted Listeria -based vaccine given with Treg-depleting agents results in slowing of PanIN progression to PDAC in a murine model (Keenan et al., 2014). Based on these data, we have initiated a clinical trial testing this vaccine in individuals at high-risk of developing pancreatic cancer. In our first Cohort [A], we have tested this vaccine in individuals at high-risk due to a known germline mutation or familial predisposition (n = 20). Our current study [Cohort B] aims to determine the safety and immunogenicity of a pooled synthetic long peptide (SLP) mKRAS vaccine with poly-ICLC adjuvant in patients with pancreatic cystic neoplasm at risk for developing PDAC and who are scheduled to undergo surgical resection . Methods: This is a single-arm, open-label phase I trial evaluating mKRAS vaccine in patients with pancreatic cystic neoplasms at risk for developing PDAC and scheduled to undergo surgical resection (n = 10). The vaccine consists of SLPs corresponding to six common mKRAS mutations: G12D, G12V, G12R, G12C, G12A, G13D admixed with poly-ICLC adjuvant. A two-dose series of the mKRAS vaccine is administered at weeks 1 and 2 followed by pancreatic surgery at week 4. Peripheral blood will be collected pre-vaccination (week 1) and post-vaccination (weeks 4 and 8). Following completion of the treatment phase, patients have the option to continue annual follow-up visits until study closure. Eligible patients must have clinical, radiographic, or histologic evidence of a pancreatic cystic neoplasm with features warranting surgical resection per the discretion of the treating hepatobiliary surgeon. Co-primary endpoints include the safety profile per NCI CTCAE v5.0 and maximal percent change of mutant-KRAS-specific T cells measured by IFNg ELISPOT at weeks 4 and 8 post-vaccination compared to pre-vaccination baseline. Correlative studies of resected specimens will include characterization of the pre-malignant microenvironment and mKRAS-specific T cell trafficking post-vaccination. Methods of analyses include bulk RNA and T cell receptor (TCR) sequencing, spatial transcriptomics, and imaging mass cytometry. Patient accrual began in December 2024 and is currently ongoing. Clinical trial information: NCT05013216 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
852的应助被橘子海采纳,获得10
刚刚
lilili的应助被核桃采纳,获得10
刚刚
djs的应助被核桃采纳,获得50
刚刚
1秒前
李健的小迷弟的应助被核桃采纳,获得10
1秒前
李健的小迷弟的应助被corleeang采纳,获得10
2秒前
杰里西发布了新的文献求助30
2秒前
zhxh完成签到,获得积分10
2秒前
安静的老师完成签到,获得积分10
2秒前
2秒前
3秒前
3秒前
key的应助被JanaL采纳,获得10
3秒前
4秒前
4秒前
CDong完成签到 ,获得积分10
4秒前
读书人完成签到,获得积分10
4秒前
不羡完成签到,获得积分10
5秒前
5秒前
qiqiqi发布了新的文献求助10
5秒前
5秒前
bkagyin的应助被无心的谷槐采纳,获得10
6秒前
7秒前
zzk完成签到,获得积分10
7秒前
Wanfeng完成签到,获得积分10
7秒前
柠A发布了新的文献求助10
7秒前
7秒前
WilliamsR1123完成签到,获得积分10
8秒前
yi发布了新的文献求助10
8秒前
NexusExplorer的应助被corleeang采纳,获得10
8秒前
今后的应助被Lily采纳,获得10
8秒前
star完成签到,获得积分10
9秒前
9秒前
希望天下0贩的0的应助被JY采纳,获得10
9秒前
9秒前
9秒前
顾矜的应助被qin202569采纳,获得10
9秒前
温婉的篮球完成签到,获得积分10
9秒前
10秒前
绝绝紫完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183142
求助须知:如何正确求助?哪些是违规求助? 9572420
关于积分的说明 21825253
捐赠科研通 7779922
什么是DOI,文献DOI怎么找? 3433850
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480124